series-a
Stage
1
Investors
About
Caldan Therapeutics is a university spin-out from the Universities of Glasgow and Southern Denmark developing selective FFA4 (GPR120) agonists targeting free fatty acid receptors for metabolic diseases, primarily aiming to treat Non-Alcoholic Steatohepatitis (NASH).
Explore Caldan Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.